Browse the evidence

Dietary restriction of branched-chain amino acids can improve insulin sensitivity and increase energy expenditure in animal models, suggesting a potential therapeutic avenue for metabolic disease.

Animal studies suggest that reducing BCAA intake might help with insulin sensitivity. However, human data is mixed, with some studies showing higher dietary BCAA linked to lower T2D risk. Do not restrict protein without medical supervision.

Pomegranate-derived phytochemicals, specifically anthocyanins (ATs) and urolithins (metabolites of hydrolyzable tannins), exhibit anti-cancer and cardioprotective bioactivities through mechanisms including aromatase inhibition, apoptosis induction, and oxidative stress reduction.

This paper reviews laboratory and animal studies showing that compounds in pomegranate (like anthocyanins and urolithins) can inhibit cancer cell growth and support heart health in controlled settings. However, it explicitly notes that these findings have not been confirmed in human clinical trials. Do not use pomegranate supplements as a treatment for cancer or heart disease without consulting a physician, as the clinical efficacy and dosage protocols for humans are not established.

Higher abundance of Dysosmobacter welbionis in the human gut is negatively correlated with Body Mass Index (BMI), fasting glucose, and glycated hemoglobin (HbA1c) in obese individuals with metabolic syndrome.

In humans with obesity and metabolic syndrome, higher levels of Dysosmobacter welbionis in the gut are associated with lower BMI, better blood sugar control, and lower HbA1c. This suggests that maintaining or increasing this bacterium may be beneficial for metabolic health.

Anthocyanin supplementation may delay the onset of neurodegenerative diseases (e.g., ALS, Alzheimer's) and improve cognitive outcomes in animal models, with mixed but promising preliminary evidence in humans.

Eating anthocyanin-rich foods like berries is a safe and potentially beneficial part of a brain-healthy diet, especially if you have a family history of neurodegenerative disease. However, do not rely on supplements as a treatment for existing cognitive decline, as human evidence is still preliminary.

Hesperidin reduces obesity and lipid accumulation by activating AMPK and PPAR signaling pathways, which regulates lipid and glucose metabolism, while simultaneously reducing inflammation via NF-κB inhibition and oxidative stress.

This paper reviews how hesperidin, a compound found in citrus fruits, may help with obesity in animal studies by improving how the body handles fat and sugar. However, it explicitly states that human clinical trials are lacking. Therefore, you cannot currently rely on hesperidin supplements for weight loss based on this evidence alone; more research is needed to establish safe and effective human dosing.

Resveratrol improves insulin sensitivity in older adults with impaired glucose tolerance, supporting its potential as an intervention to delay aging based on its effects on the insulin/IGF-1 pathway.

Resveratrol may improve insulin sensitivity in older adults with impaired glucose tolerance. While more research is needed, it represents a potential dietary supplement to support metabolic health. Consult a healthcare provider before starting.

Obesity may be characterized by a 'NEAT Conservers' phenotype, where the brain's response to signals that stimulate movement (like orexin) is dulled, leading to low NEAT and weight gain.

Understand that your brain may have a 'dulled' response to movement signals, making it harder to stay active. This is not a moral failing. Use environmental strategies (like walking desks) and behavioral techniques (like STRIPE) to overcome this biological resistance.

For stroke rehabilitation, exercise interventions are more effective than anticoagulant or antiplatelet drug therapies in reducing mortality.

If you are recovering from a stroke, engaging in prescribed physical activity and rehabilitation exercises may offer greater protection against death than relying solely on blood-thinning medications like anticoagulants or antiplatelets. Consult your doctor for a safe, tailored exercise program.

Time-Restricted Feeding (TRF) shows profound metabolic benefits in rodents (improved glucose tolerance, reduced adiposity/steatosis) even without energy restriction, but human studies are sparse, mixed, and methodologically limited, with some showing worsened glycaemia.

If you try Time-Restricted Feeding (TRF), limit your eating window to 10-12 hours daily. Be aware that human evidence is mixed; some studies show worsened glycaemia, possibly due to timing (e.g., evening eating) or methodological issues. Monitor your blood glucose and lipids, and consider experimenting with earlier eating windows if possible, as this may align better with circadian biology.

Caloric restriction extends lifespan in humans by modulating epigenetic markers, specifically through DNA hypermethylation of the p16INK4a gene promoter and SIRT1-mediated deacetylation.

Research suggests that the longevity benefits of CR in humans may involve specific epigenetic changes, such as the silencing of the p16INK4a gene (a marker of cellular senescence) via DNA methylation and SIRT1 activation. This provides a biological basis for why CR might slow aging, though it does not yet translate to a guaranteed lifespan extension protocol for individuals.

Frequent physical activity in nature is weakly connected to better sleep quality, but this connection is not robust and is outweighed by other factors such as disability or life events.

Do not rely on exercising in nature to fix sleep problems. The study found no robust link between nature-based exercise and sleep quality after controlling for other life factors. Focus on sleep hygiene and consistent exercise regardless of location.

Regular consumption of non-nutritive sweeteners (NNS) does not have conclusive evidence for beneficial or harmful effects on major health outcomes including appetite, short-term food intake, cancer risk, diabetes risk, dental caries, weight gain, or obesity in healthy subjects.

Current scientific evidence does not support the idea that non-nutritive sweeteners (like aspartame, sucralose, or stevia) are inherently harmful or beneficial for weight, cancer, or diabetes risk in healthy people. While some studies show mixed results on appetite, the overall body of research does not confirm significant health benefits or harms. You can use them as part of a balanced diet without expecting specific health outcomes based on current data.

Post-pyloric tube feeding increases the percentage of total nutritional targets delivered to critically ill patients compared to gastric feeding, likely due to improved tolerance and fewer feeding interruptions.

Placing the feeding tube in the small intestine (post-pyloric) allows critically ill patients to receive a slightly higher percentage of their prescribed nutritional targets compared to stomach feeding. This is likely because the small intestine tolerates feeding better, leading to fewer interruptions. However, this improved nutrition delivery has not been shown to translate into shorter ICU stays or lower mortality rates. The benefit is modest and comes with the challenge of more difficult tube placement.

Weight loss interventions in overweight and obese men do not show consistent or significant improvements in fertility outcomes due to a lack of high-quality randomized studies.

For overweight or obese men seeking to improve fertility, current evidence is insufficient to recommend specific weight loss protocols, though general health benefits apply. More research is needed.

Omega-3 fatty acid supplementation (specifically DHA) shows promise in preclinical models for reducing beta-amyloid and oxidative stress, but current clinical evidence is insufficient to recommend it for the general prevention or treatment of cognitive frailty or dementia.

Focus on obtaining Omega-3 fatty acids through dietary sources like fish rather than supplements for general cognitive health. Do not use Omega-3 supplements as a primary treatment or prevention strategy for dementia, as current clinical evidence is insufficient to support this use, unless you have a specific deficiency.

Exercise induces a phenotypic switch in white adipose tissue (WAT) to thermogenic 'beige' adipocytes via multiple mechanisms including myokine secretion (irisin, IL-6, meteorin-like), natriuretic peptides, and angiogenesis, although the metabolic benefit and necessity of this process in humans remain uncertain.

Exercise likely triggers biological changes in fat tissue (browning) in animals, but this hasn't been proven to happen or help in humans. Don't rely on 'browning' as a weight loss strategy; focus on the proven benefits of exercise like improved insulin sensitivity and cardiovascular health.

Intermittent Fasting (IF) in normal-weight subjects may cause adverse metabolic effects, including increased visceral fat, muscle insulin resistance, and increased intramyocellular triglycerides, which are not seen with Intermittent Energy Restriction (IER) or Continuous Energy Restriction (CER).

If you are already lean, avoid total fasting (0 calories). It may cause your body to store fat in your muscles and liver, worsening insulin sensitivity. Stick to partial restriction (eating some food) if you want to try intermittent fasting.

Asprosin promotes hepatic glucose production (gluconeogenesis) and stimulates appetite (orexigenic effect) via central and peripheral signaling pathways, although the reproducibility of these effects is controversial due to reagent quality issues.

Research suggests asprosin might increase hunger and liver glucose output, but studies are inconsistent. Some early positive findings may have been due to experimental errors. Until the science is settled, focus on proven methods for managing hunger and blood sugar like balanced nutrition and exercise.

Asprosin may have a protective role in cardiovascular disease by preventing cardiomyocyte apoptosis and improving mesenchymal stromal cell function in myocardial infarction models.

Current research indicates asprosin might protect heart cells from damage in diabetic conditions and improve stem cell therapy outcomes for heart attacks. However, this is still in early research stages. For now, managing cardiovascular risk factors remains the standard of care.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.

There is no single 'best' combination therapy yet. The field is still debating whether to maximize GLP-1, add glucagon, or add GIP. Current trials are testing different ratios (e.g., 1:1 vs 5:1 GLP-1:glucagon). Patients should expect that these therapies are evolving and that side effects (nausea, hyperglycemia) may limit the dose that can be tolerated.

GLP-1 receptor agonists exhibit neuroprotective effects in animal models of Alzheimer's and Parkinson's disease, potentially by crossing the blood-brain barrier and reducing amyloid-beta accumulation.

Current evidence for neuroprotection from GLP-1 agonists comes primarily from animal studies, showing potential to protect against Alzheimer's and Parkinson's disease mechanisms. While promising, clinical data in humans is still limited, and these drugs are not yet approved for cognitive disorders.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.